Vanguard Group Inc Galecto, Inc. Transaction History

Vanguard Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.52 - $0.78 $2,028 - $3,042	3,900 Added 1.79%	221,200 $159,000
Q3 2023 Nov 14, 2023	BUY	$0.56 - $3.17 $39,951 - $226,154	71,342 Added 48.88%	217,300 $156,000
Q2 2023 Aug 14, 2023	BUY	$1.68 - $2.84 $134,070 - $226,643	79,804 Added 120.63%	145,958 $367,000
Q1 2023 May 15, 2023	BUY	$1.21 - $2.86 $32,160 - $76,015	26,579 Added 67.16%	66,154 $131,000
Q4 2022 Feb 10, 2023	BUY	$1.06 - $58.5 $5,677 - $313,326	5,356 Added 15.65%	39,575 $45,000
Q2 2022 Aug 12, 2022	BUY	$1.22 - $2.74 $10,383 - $23,320	8,511 Added 33.11%	34,219 $59,000
Q4 2021 Feb 14, 2022	SELL	$2.3 - $3.58 $4,705 - $7,324	-2,046 Reduced 7.37%	25,708 $78,000
Q3 2021 Nov 12, 2021	BUY	$3.59 - $5.0 $11,516 - $16,040	3,208 Added 13.07%	27,754 $99,000
Q2 2021 Aug 13, 2021	BUY	$4.63 - $8.0 $113,647 - $196,368	24,546 New	24,546 $124,000

21.2K

Ticker GLTO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,395,700
Market Cap $120M
Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.